Aprea
Stockholm
About Aprea
Aprea is a biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea Therapeutics was established in 2003 in Stockholms Lan, Sweden by Klas Wiman and Galina Selivanova.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $145.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nasdaq:APRE
- Website: aprea.com
- Phone: +460850884504
Industries & Categories
Biotechnology, Health Care, Medical, Personal Health, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/aprea-43143 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.